Breast Cancer Treatment Delays in a Majority Minority Community: Is There a Difference?
Breast Cancer Treatment Delays in a Majority Minority Community: Is There a Difference?
San Antonio Breast Cancer Symposium registration open
Registration is open for the 46th annual San Antonio Breast Cancer Symposium, Dec. 5–9, at the Henry B. Gonzalez Convention Center. Experts will lead symposium discussions on clinical, translational and basic research. Attendees will receive information on experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease. Click here to register.
Disparities discussed at San Antonio Breast Cancer Symposium
Researchers from the Mays Cancer Center at UT Health San Antonio presented results of multiple lines of study during the San Antonio Breast Cancer Symposium, operated in conjunction with the American Association of Cancer Research.
postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a
postMONARCH is a Phase 3, global, multicenter, randomized, double-blind, placebo-controlledstudy in participants with HR+, HER2- advanced or metastatic breast cancer. This study willenroll adults who experienced disease progression on a CDK4 & 6 inhibitor and an AI in thefirst-line setting or relapse on/after a CDK4 & 6 inhibitor with ET in the adjuvant setting.
Breast cancer survivor clinical trial offers recovery and hope
Lindsay Fry is a breast cancer survivor who was first diagnosed in 2019. Her treatment regimen of surgery, radiation and chemotherapy began in fall 2019. Shortly after completing her treatment, Fry became the first participant in a new clinical trial at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) that aims to help breast cancer survivors regain their energy and remain cancer free.
Targeting aberrant replication and DNA repair events for treating breast cancers
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicianâ??s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or
This is an international, multicenter, open-label, randomized, Phase 3 study in patients withlocally advanced, inoperable or metastatic triple-negative breast cancer (TNBC) who have not received previous therapy for advanced disease and whose tumors are either: PD-L1 negative at screening (defined using the PD-L1 IHC 22C3 assay as tumors with a combined positive score (CPS) < 10), OR PD-L1 positive at screening (defined using the PD-L1 IHC 22C3 assay as tumors with a CPS ≥ 10) if they previously received a checkpoint inhibitor in the adjuvant or neoadjuvant setting.